Retevmo: Indication and Usage



Retevmo (selpercatinib) is a kinase inhibitor recommended by healthcare professionals to treat patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, and locally advanced or solid metastatic tumors with a RET gene fusion. 

Indications and Usage

RET Fusion-Positive Non-Small Cell Lung Cancer

Healthcare professionals recommend Selpercatinib for treating patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). 

Non-small cell lung cancer is one of the common types of lung cancer. With this disease, cancer cells begin in your lung tissues. Non-small cell lung cancer grows slowly compared to small cell lung cancer — but it often spreads to other parts of your body by the time it's diagnosed. 

RET-Mutant Medullary Thyroid Cancer 

The medicine Retevmo (Selpercatinib) is used by healthcare providers to treat RET-Mutant Medullary Thyroid Cancer. 

Medullary thyroid cancer (MTC) is cancer that forms in the thyroid. The thyroid is a gland found in the front of your neck, just beneath Adam's apple, and it is responsible for sending out hormones to the rest of the body. The inside of the thyroid is known as the medulla.

RET Fusion-Positive Thyroid Cancer

Healthcare professionals recommend Retevmo 40 mg and 80 mg for treating adult and pediatric patients 12 years of age with advanced or metastatic thyroid cancer with a RET gene fusion. 

Metastatic thyroid cancer, also referred to as stage 4 thyroid cancer, has spread from the thyroid gland to other areas of the body. Thyroid cancer is an uncontrollable growth of cells that begins in the thyroid. The thyroid gland is butterfly-shaped and found at the base of the neck, just below Adam's apple.

Other RET Fusion-Positive Solid Tumors

Retevmo (Selpercatinib) is recommended for treating locally advanced or metastatic solid tumors with a RET gene fusion that has progressed on or following prior systemic therapy or who have no satisfactory substitute treatment options in adult patients.

An abnormal mass of tissue that usually does not have cysts or liquid areas. Solid tumors could not be cancerous or cancerous. 

Recommended Dosage

Healthcare professionals would select patients for treatment with Retevmo based on the presence of a RET gene fusion (NSCLC or thyroid cancer) or specific RET gene mutation (MTC) in tumor specimens or plasma. 

One can take Selpercatinib with or without food unless coadministered with a proton pump inhibitor (PPI).

The recommended Retevmo dosage based on body weight is:

  •  Less than 50 kg: 120 mg
  •  50 kg or greater: 160 mg

One should take Retevmo orally twice daily (approx. every 12 hours) until disease progression or unacceptable toxicity. 

Note: Retevmo dosage depends upon the type of disease and the patient's health history.

Reference: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf

Comments

Post a Comment

Popular posts from this blog

Buy Trodelvy sacituzumab govitecan-hziy in India

  Trodelvy Overview: Trodelvy is widely prescribed by Oncologists for the treatment of patients with HR+/HER2- Metastatic Breast Cancer, Metastatic Triple-Negative Breast Cancer (mTNBC), and Metastatic Urothelial Cancer (mUC). It is considered a promising treatment option for those who are not ideal candidates for some conventional therapies. Developed by Immunomedics, Trodelvy 180 mg and Trodelvy 200 mg are two available commercial strengths. Worldwide, Trodelvy is promoted and facilitated by Gilead Sciences. Trodelvy is first approved on 22 April 2020. It is given by intravenous (IV) infusion by a health specialist. The medication received its (European Medicines Agency) EMA approval in October 2021. Trodelvy 180 mg and 200 mg injections are yet to be approved in India. The cost of Trodelvy in India usually depends on international factors. Buy Trodelvy from a Reliable Source: Many suppliers who are not authorized to handle or supply life-saving medicines such as Trodelvy found to b
Read more

What is Non-Small Cell Lung Cancer? What are the stages of NSCLC?

Image
NSCLC, the most common form of lung cancer. It occurs when the healthy cells in the lung change and start growing in an abnormal way, forming a specific mass addressed as tumor, lesion, or nodule. A tumor may develop anywhere in the lung and could be cancerous or benign. A cancerous tumor mainly is malignant, means, it has potential in order to spread to the rest part of the body. A benign tumor is the tumor that can grow but can not spread.  Non-Small Cell Lung Cancer (NSCLC) occurs in the epithelial cells. Doctors can also describe this form of Cancer (NSCLC) based on the type of the epithelial cell where the cancer usually starts.  Adenocarcinoma starts in cells that produce mucus.  Squamous carcinoma basically developed in the cells that line the airways.  Large cell carcinoma usually begins in the cells other than the two types which are described above.  It’s necessary for healthcare providers to distinguish between lung cancer that begins in the squamous cells from lung cancer
Read more

Trodelvy: All about the drug

Image
Indication and Usage The medicine Trodelvy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate drug, which is used in the treatment of adults suffering from locally advanced or metastatic triple-negative breast (mTNBC) cancer, HR+/HER2- metastatic breast cancer, and locally advanced or metastatic urothelial cancer (mUC). It is used when it is not possible to remove cancer with surgery. Trodelvy  comes in the form of single-dose vials in 180 mg for intravenous infusion. Dosage Its dosage is based on body weight, and the recommended dosage is 10 mg/kg administered intravenously once weekly on the first day and eighth day of a repeating 21-day cycle. Administration First infusion: The drug is infused in the body for 3 hours, and during the infusion, the patient is observed for any adverse reaction caused by the infusion. After 30 minutes of infusion, observation should be done again to check for any post-infusion reaction. Subsequent Infusion: If the drug is tolerated in t
Read more